Recently, Acuitylab Bioscience was honoured to participate in the APMS-HKVRS 2025 Joint Congress, connecting with ophthalmologists, myopia and vitreoretinal specialists and experts from Hong Kong, the Greater Bay Area, and across the Asia-Pacific region. Our team received recognition for supporting the meeting and showcased our Refractive Surgery Genetic Test for corneal dystrophy – a screening that detects 5 common TGFBI mutations and helps to prevent irreversible corneal complications following LASIK or SMILE procedures.

The congress featured rich and forward-looking content, covering a broad spectrum from innovative vitreoretinal surgical techniques to the latest research developments in myopia management. Many clinicians who visited our booth affirmed the significant value of integrating precise genetic insights into surgical decision-making and lifelong patient management.

“We are committed to enhancing the safety of refractive surgery through personalized genetic diagnostics,” said Mr. Rhys Chan, Chief Executive Officer at Acuitylab Bioscience.

Acuitylab sincerely thanks every delegate who visited our booth, attended our presentations, and shared valuable insights. We look forward to deepening our collaborations to actively promote safer, patient-centred eye care solutions.

About Acuitylab Bioscience

Founded in 2024, Acuitylab Bioscience is built on over two decades of expertise in DNA and medical testing in Hong Kong. Our mission is to deliver highly accurate results and innovative genetic insights that meet the highest standards in healthcare diagnostics.

As a sister company to Avellino Korea, a recognized leader in ophthalmic genetic testing with over 1 million tests performed to date—helping prevent early blindness in thousands of patients through early detection — Acuitylab is committed to expanding our footprint in precision diagnostics, with a strong focus on ophthalmology, while continuing to deliver trusted solutions for our partners and clients.